$UNH

Conway Patrick Hugh sold $205K of UNH

Conway Patrick Hugh (Chief Executive Officer, Optum) sold 500 shares of UNITEDHEALTH GROUP INC (UNH) at $410.00 ($0.20M total) on 2026-08-05.

Original reporting
SEC EDGAR · Conway Patrick Hugh
Published Aug 7, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$UNH
Neutral
medium confidence
Mentioned
$UNH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UNHNeutralLow
01

Why it matters

The only new information is the disclosed sale: 500 shares at $410 for about $205,000, with holdings after the transaction of 16,497 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no accompanying guidance, earnings, regulatory, or deal catalyst in the text.

03

What to watch

The article does not state whether the sale was part of a broader pattern, whether other insiders sold/bought, or whether there were concurrent compensation events that could explain the transaction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07, transaction dated 2026-08-05

Background

The filing is an SEC Form 4 insider transaction for UnitedHealth Group Inc, reported by Conway Patrick Hugh (CEO, Optum).

Company-level read

Ticker impact

$UNHNeutralMedium confidence
Context

UNH CEO of Optum, Conway Patrick Hugh, filed a Form 4 open-market sale of 500 shares at $410 on 2026-08-05.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales can be routine and are not, by themselves, a new operating or guidance catalyst. The article provides transaction size, price, and post-sale holdings, but no accompanying company-specific news.

Market effects

Minimal; single-insider transaction in a large managed-care name does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

The sale may be tax or diversification related, especially since the filing does not provide context for motive and insider sales are often pre-planned even when not explicitly labeled as 10b5-1.

Key entities

  • UnitedHealth Group Inc

    Subject of the Form 4 insider transaction disclosure.

  • Conway Patrick Hugh

    Optum CEO and reporting insider who sold shares.

  • Optum

    Operating unit where the insider serves as CEO.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

UNH Stock Becomes Dow’s Biggest Driver Back To 50,000 — Will Trump Tailwinds Spark Another Leg Higher?

UnitedHealth Group (UNH) stock has surged 47% since February 10, becoming the best-performing Dow component. The company expects margin recovery by 2028, with Optum Health performing better than expected. Bank of America raised its price target to $420. Trump's recent UNH purchases added momentum. UNH plans significant AI investments, aiming for a 30% reduction in prior authorization requirements by 2027.

$UNHMed

UnitedHealth Stock Rises 39% in 6 Months: Should Investors Still Buy?

UnitedHealth Group (UNH) shares rose 38.8% in 6 months, outperforming peers and the S&P 500. Medical-cost trends improved, with the medical care ratio decreasing to 85.3%. The company is focusing on profitability, reducing exposure to weaker businesses, and returning capital to shareholders. Earnings estimates for 2026 and 2027 have been revised upward, with EPS growth of 21.2% and 13.7% expected, respectively. UNH trades at 18.51X forward earnings, below its 5-year median.

$UNHMedAI 8/10

UnitedHealth Stock Is Up 39% in Six Months.

UnitedHealth Group (UNH) stock rose 38.6% in six months, driven by two consecutive earnings beats and raised guidance. Analysts' average price target is $475, 19% above the current price. The company plans to reduce prior authorization requirements by 30% by year-end, aiming to improve operational efficiency. TIKR's model projects UNH stock to reach $722 by December 2030, implying an 80% total return.

$UNHMed

How many employees does UnitedHealth have in 2026? Locations & layoffs explained

UnitedHealth Group, a Dow Jones component, reported over 390,000 employees globally as of 2025, with 90,000 affiliated physicians. In 2026, it conducted layoffs, reduced clinics, and adjusted its revenue outlook to $439B, down 2% from 2025. Q2 earnings guidance was raised to $19.50-$20 per share, citing cost management and AI. CEO Brian Thompson was killed in 2024, sparking public backlash against the company.

$UNHMed

UnitedHealth’s Policy Change Opens a New Chapter for its Insurance Business

UnitedHealthcare, a unit of UnitedHealth Group (UNH), will remove prior authorization for 30% of healthcare services by 2026, starting October 1. The change covers various services and plans, aiming to reduce administrative burdens and improve provider and member experiences. The company also plans to accelerate payments for rural hospitals. The move may improve relationships but could increase healthcare utilization and costs, according to the company.

$CVXMedAI 8/10

Dow Falls 419 Points as Bond Yields Rise: Stock Market Today

The Dow fell 419 points as bond yields rose, driven by Middle East tensions and rising oil prices. Energy stocks like Chevron (CVX) gained, while tech stocks declined. Apple (AAPL) rose 2.6% under new leadership. Palo Alto Networks (PANW) dropped 5.2% ahead of earnings. Novartis (NVS) surged 6.0% on positive drug trial results. The 10-year Treasury yield hit 4.792%.